2019 ASHEcon Diversity Scholarship

from ASHEcon at http://bit.ly/2XnNPzU on February 28, 2019 at 10:40PM In an effort to encourage participation by underrepresented communities, the American Society of Health Economics (ASHEcon) jointly with the National Institute of Aging (NIA) funded Center on the Demography and Economics of Health and Aging at Stanford University are offering up to twenty scholarships aimed […]

AcademyHealth Members Publish Research on Substance Use Treatment, Health Policy Recommendations, and More

from AcademyHealth Blog at http://bit.ly/2UdGiBF on February 28, 2019 at 03:01PM AcademyHealth Members Publish Research on Substance Use Treatment, Health Policy Recommendations, and More The January issue of Health Affairs featured several studies authored by AcademyHealth members. Members contributed research to a wide range of pressing issues including substance use and treatment, payment and costs, […]

Shafrin: ICER Tackling ‘Pressing Issue’ With Value-Over-Time Reports

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2IKmh4v on February 28, 2019 at 02:32PM The Institute for Clinical and Economic Review’s (ICER) decision to do reports on a drug’s value over time is one that “addresses a pressing issue,” according to Jason Shafrin, a health care economist. Value and estimated value are dynamic variables that […]

Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA

from News at http://bit.ly/2H7yoGq on February 28, 2019 at 02:07PM In a new OHE Seminar Briefing, Dr Steven Pearson, President of the Institute for Clinical and Economic Review (ICER), discusses early experiences of using HTA to assess Gene Therapy, setting out four challenges. First, uncertainty about clinical effectiveness makes it difficult for ICER to suggest […]

Embryo adoption

from Market Design at http://bit.ly/2Tsd5pP on February 28, 2019 at 01:24PM The NY Times has the story: Embryo ‘Adoption’ Is Growing, but It’s Getting Tangled in the Abortion Debate "As evangelical Christians, Paul and Susan Lim believe that life begins at conception. So when they decided to have a third child, in vitro fertilization was […]

Using Evidence for Decision-Making in Health Benefits Package Design: iDSI co-hosts major event, bringing together policy-makers from seven North Eastern Indian States

from iDSI at http://bit.ly/2Tp2HyQ on February 28, 2019 at 12:04PM As India moves towards the achievement of Universal Health Coverage (UHC), finding robust and evidence-based answers to the challenges of defining which services should be publicly funded, for whom and how, becomes increasingly important. The introduction of ‘Modicare’, the nascent health insurance scheme announced out […]

Sachverständigenrat um Jonas Schreyögg nimmt Arbeit auf

from HCHE News at http://bit.ly/2BVy62a on February 28, 2019 at 11:59AM Im Rahmen einer feierlichen Zeremonie überreiche Bundesgesundheitsminister Jens Spahn am 27. Februar den neuen und wiedernannten Mitgliedern des Sachverständigenrats Gesundheit, darunter HCHE-Direktor Professor Jonas Schreyögg, die Ernennungsurkunden. Anschließend trafen sich die Mitglieder zur konstituierenden Sitzung und nutzen diese, um den ersten Vorsitzenden (Allgemeinmediziner Prof. […]

The unobserved pattern of material hardship and health among older Americans

from Journal of Health Economics at http://bit.ly/2Ejrlr6 on February 28, 2019 at 10:43AM Publication date: Available online 28 February 2019 Source: Journal of Health Economics Author(s): Paolo Li Donni Abstract This paper investigates the relationship between self-reported health and material hardship among older Americans. Differently from income-based measures, material hardship provides a more specific description […]

Does hospital competition improve efficiency? The effect of the patient choice reform in England

from Health Economics at http://bit.ly/2T6V80w on February 28, 2019 at 08:47AM Abstract We use the 2006 relaxation of constraints on patient choice of hospital in the English NHS to investigate the effect of hospital competition on dimensions of efficiency including indicators of resource management (admissions per bed, bed occupancy rate, proportion of day cases, and […]

Congress grills pharma executives

from Healthcare Economist at http://bit.ly/2BXduXb on February 28, 2019 at 08:03AM Seven CEOs from large pharmaceutical firms were brought before Congress today. And they got an earful from both Demogratic and Republican Congressmen. The executives were critique for selling too many opioids. They were critiqued for legal manuevers to extend brand name drugs’ patent life. […]

Why prevent when it does not pay? Prevention when health services are credence goods

from Health Economics at http://bit.ly/2H761rL on February 28, 2019 at 02:46AM Summary This article identifies information asymmetries and the corresponding problem of overtreatment as a possible source of prevention and health disparities when patients differ with respect to their health risk. It analyzes preventive health behavior (primary prevention) and preventive health‐care utilization (secondary prevention) in […]

Is it time to ditch the private health insurance rebate? It’s a question Labor can’t ignore

from The Conversation – health economics at http://bit.ly/2H23jUF on February 27, 2019 at 09:00PM Premium subsidies encourage Australians to take out and keep private health insurance. Shutterstock This is part of a major series called Advancing Australia, in which leading academics examine the key issues facing Australia in the lead-up to the 2019 federal election […]

Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide Initiation

from PharmacoEconomics – Open at http://bit.ly/2T5WoAO on February 27, 2019 at 06:13PM Abstract Background Dofetilide is a class III antiarrhythmic drug indicated for the conversion and maintenance of normal sinus rhythm in symptomatic patients with atrial fibrillation/atrial flutter. Delay in initiation of dofetilide therapy may increase the duration of hospitalization from two nights to three […]

Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0–9 Years with Pertussis in Catalonia (Spain)

from PharmacoEconomics – Open at http://bit.ly/2T2lLUo on February 27, 2019 at 06:13PM Abstract Objectives The aim of this study was to assess direct health costs in children with pertussis aged 0–9 years who were vaccinated, partially vaccinated, and unvaccinated during childhood, and to assess the association between pertussis costs and pertussis vaccination in Catalonia (Spain) in […]

Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective

from PharmacoEconomics – Open at http://bit.ly/2Ehi7vr on February 27, 2019 at 06:13PM Abstract Background In Australia, the reimbursement of botulinum neurotoxin-A (BoNT-A) on the Pharmaceutical Benefits Scheme for the treatment of moderate to severe spasticity of the upper limb following a stroke (PSS-UL) is restricted to four treatment cycles per upper limb per lifetime. This […]

Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations

from PharmacoEconomics – Open at http://bit.ly/2T7YVLb on February 27, 2019 at 06:13PM Abstract Time trade-off (TTO) is an established method in health economics to elicit and value individuals’ preferences for different health states. These preferences are expressed in the form of health-state utilities that are typically used to measure health-related quality of life and calculate […]

Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)

from PharmacoEconomics – Open at http://bit.ly/2EfzHjE on February 27, 2019 at 06:13PM Abstract Background This study’s purpose was to assess the minimal important difference (MID) for the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM–AGHD), a patient-reported outcome measure assessing growth hormone deficiency (GHD) impacts. The measure was demonstrated to have adequate psychometric measurement properties, and […]

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use

from PharmacoEconomics – Open at http://bit.ly/2T3Kp6R on February 27, 2019 at 06:13PM Abstract Background Disease progression and acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF) are associated with high morbidity and mortality. They usually require a visit to a specialist or a general practitioner (GP) in less severe cases or hospitalisation in more severe […]